SEC Form 4 · accession 0001840706-26-000265
SOPHiA GENETICS SA · SOPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philippe Menu
Officer — Chief Medical Officer
Period of report
Jul 27, 2026
Accepted (ET)
Jul 28, 2026 · 4:03 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001840706
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Jul 27, 2026 | S | 5,000 | $5.6611 | D | 223,387 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.57 to $5.83, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.